[Effect of recombinant human granulocyte colony-stimulating factor on neutrophil morphology, function and phenotype in patients with acute leukemia undergoing chemotherapy]
- PMID: 16403274
[Effect of recombinant human granulocyte colony-stimulating factor on neutrophil morphology, function and phenotype in patients with acute leukemia undergoing chemotherapy]
Abstract
This study was to explore the effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on neutrophil morphology, function and phenotype in patients with acute leukemia undergoing chemotherapy. Neutrophil morphology was observed under microscope with oil immersion; phagocytotic function was examined by measuring the amount of hydrogen peroxide produced by neutrophil; chemotaxis was analyzed by agarose method; oxidative burst was analyzed by flow cytometry using immunofluorescence technique; neutrophil phenotype was analyzed by flow cytometry and immunofluorescence techniques. The results showed that after rhG-CSF administration, the increased "toxic" granulation, vacuoles and Döhle bodies were observed in neutrophils of patients with acute leukemia. Compared with normal control, the functions of phagocytosis, chemotaxis, oxidative burst of neutrophil were impaired after chemotherapy, while these functions were enhanced and returned to normal level or even to be exceeded after administration of rhG-CSF. In patients with acute leukemia the neutrophil presented significantly higher expression of CD64 and CD62L than that in normal control, and a mild increase of CD64 expression and significant increase of CD62L expression were found in patients after rhG-CSF treatment. No modifications of CD16, CD32, CD14 and CD11b expression were detected in these patients before or after G-CSF administration. It is concluded that rhG-CSF administration can modify the morphology, function and phenotype of neutrophils in the patients with acute leukemia undergoing chemotherapy, and these modifications of neutrophil behavior may be supposed to be a reason for the enhancement of organism anti-infection ability.
Similar articles
-
Clinical effects of recombinant human granulocyte colony-stimulating factor in leukemia patients: a phase I/II study.Exp Hematol. 1989 Sep;17(8):853-8. Exp Hematol. 1989. PMID: 2475358
-
Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission.Intensive Care Med. 2003 Jun;29(6):904-914. doi: 10.1007/s00134-003-1734-y. Epub 2003 Apr 8. Intensive Care Med. 2003. PMID: 12682721 Clinical Trial.
-
Granulocyte colony-stimulating factor (G-CSF) administration increases PMN CD32 (FcRII) expression and FcR-related functions.Haematologica. 1995 Mar-Apr;80(2):150-4. Haematologica. 1995. PMID: 7543071
-
Effects of recombinant human granulocyte colony-stimulating factor administration on neutrophil phenotype and functions.Haematologica. 1997 Sep-Oct;82(5):606-16. Haematologica. 1997. PMID: 9407734 Review.
-
Old drug, new use: Recent advances for G-CSF.Cytokine. 2024 Dec;184:156759. doi: 10.1016/j.cyto.2024.156759. Epub 2024 Sep 17. Cytokine. 2024. PMID: 39293182 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials
Miscellaneous